Development and commercialization of innovative oncology drugs, focusing on indications where existing treatments are limited or inadequate.
E
CSR Analysis score
The organization does not position itself on any CSR axis.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: May 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Takeda
B
Development and commercialization of innovative medicines in various therapeutic areas, including gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
Orphan Europe
B
Development and commercialization of drugs for rare diseases.
Johnson & Johnson
B
Development of innovative medicines and medical technologies for complex diseases, including oncology, immunology, neuroscience, cardiopulmonary, and specialty ophthalmology.
Initiatives identified among leaders
Objectif 2028 : 80 % des fournisseurs avec cibles basées sur la science
“Johnson & Johnson vise à ce que 80 % de ses fourni...” - Johnson & JohnsonUtiliser des énergies renouvelables
“Orphan Europe utilise des énergies renouvelables, ...” - Orphan EuropeProgramme de durabilité pour évaluer et accompagner les fournisseurs sur leurs impacts environnementaux et sociaux.
“Johnson & Johnson a mis en place un programme de d...” - Johnson & Johnson56% of similar organizations communicate on CSR issues
+1579 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports